Pharmacology and clinical experience with repaglinide

Bibliography

• DAVIES MJ, RAYMAN G, GRAY IP, DAY JL, HALES CN: Insulin deficiency and increased plasma concentra-tion of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. DiabeL Med. (1993) 10 (4) :313–320.
   PubMed Web of Science ®Google Scholar
• LERNER RL, PORTE D: Acute and steady-state insulinresponses to glucose in nonobese diabetic subjects. J. Clin. Invest. (1972) 5 1 (7):1624–1631.
   Google Scholar
• POLONSKY KS, GIVEN BD, HIRSCH LJ et al.: Abnormalpatterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl. J. Med. (1988) 318 (19):1231–1239.
   PubMed Web of Science ®Google Scholar
• •Evidence that Type 2 diabetes is associated with altered insulin secretion in response to meals arising from beta-cell dysfunction.
   Google Scholar
• Hypertension in Diabetes Study 1 (HDS): Prevalence of hypertension in newly presenting Type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J. Hypertens. (1993) 11(3):309–317.
   PubMed Web of Science ®Google Scholar
• Hypertension in Diabetes Study II (HDS): Increased risk of cardiovascular complications in hypertensive Type 2 diabetic patients. J. Hypertens. (19 9 3) 11(3):319–325. [Erratum in J. Hypertens. (1993) 11(6):681[
   Google Scholar
• TURNER RC, MILLNS H, NEIL HA et al: Risk factors forcoronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ (1 9 9 8) 316(7134)823–828.
   Google Scholar
• THE DIABETES CONTROL AND COMPLICATIONS TRIALRESEARCH GROUP: The absence of a glycemic threshold for the development of long-term complica-tions: the perspective of the Diabetes Control and Complications Trial. Diabetes (1996) 45 (10) :1289–1298.
   PubMed Web of Science ®Google Scholar
• BALKAU B, SHIPLEY M, JARRETT RJ et al: High bloodglucose concentration is a risk factor for mortality in middle-aged non-diabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study and the Helsinki Policemen Study. Diabetes Care (1998) 21(3):360–367.
   Google Scholar
• TOMINAGA M, EGUCHI H, MANAKA H, IGARASHI K,KATO T, SEKIKAWA A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata diabetes study. Diabetes Care (1999) 22 (6):920–924.
   PubMed Web of Science ®Google Scholar
• •Recent confirmation that impaired glucose tolerance is a risk factor for cardiovascular disease, also highlighting the differ-ence between impaired glucose tolerance and impaired fasting glucose.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 3 52 (9130:837–853.
   Google Scholar
• ••Demonstration that intensive glycaemic control reduces therisk of microvascular complications in patients with Type 2 diabetes. Interestingly does not show a significant effect on macrovascular disease.
   Google Scholar
• BERGER W: Incidence of severe sideeffects duringtherapy with sulfonylureas and biguanides. Horm. Metab. Res. (1985) 15\(Supp1.1):111–115.
   Google Scholar
• BRODOWS RG: Benefits and risks with glyburide andglipizide in elderly NIDDM patients. Diabetes Care (1992) 15(0:75–80.
   PubMed Web of Science ®Google Scholar
• Physician's Guide to Non-Insulin-Dependent (Type II)Diabetes: Diagnosis and Treatment (2nd edition). Rifkin H (Ed.) American Diabetes Association, Alexandria, VA, USA (1988).
   Google Scholar
• GROMADA J, DISSING S, KOFOD H, FROKJAER-JENSEN J:Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia (1 9 9 5) 38 (9): 1025–1032.
   Google Scholar
• FUHLENDORFF J, RORSMAN P, KOFOD H et al: Stimula-tion of insulin release by repaglinide and glibencla-mide involves both common and distinct processes. Diabetes (1998) 47(3):345–351.
   PubMed Web of Science ®Google Scholar
• ••Comparison of the mechanisms of action of repaglinide andglibenclamide.
   Google Scholar
• KOFOD H, FUHLENDORFF J: Effect of repaglinide oninsulin release in isolated islets of Langerhans is unaffected by metabolic stress induced by dinitro-phenol. Eur. J. Endocrinol. (1995) 132 (Suppl. 0:14.
   Google Scholar
• BAKKALI-NADI A, MALAISSE-LAGAE F, MALAISSE WJ:Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency. Diabetes Res. (1994) 27 (2) 81–87.
   PubMedGoogle Scholar
• KOFOD H, FUHLENDORFF J: Repaglinide compared toglibenclamide in isolated mouse islets by perifusion. Diabetologia (1995) 38\(Suppl. 1):A195.
   Google Scholar
• MARK M, GRELL W: Hypoglycaemic effects of the novelantidiabetic agent repaglinide in rats and dogs. Br. J. Pharmacol. (1997) 121(8):1597–1604.
   PubMed Web of Science ®Google Scholar
• MARK M, EPPLE M, GRELL W: Stereoselective antihyper-glycaemic effects of the benzoic acid derivative AG-EE 388 in vivo. Diabetologia (1997) 40\(Suppl. 1):A372.
   Google Scholar
• BOEHRINGER INGELHEIM: Testing specifications.(1996).
   Google Scholar
• HATORP V, OLIVER S, SU CA: Bioavailability ofrepaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. (1998) 36(12):636–641.
   PubMed Web of Science ®Google Scholar
• •Demonstration that the pharmakinetic properties of repaglinide make it ideally suited for prandial glucose regulation.
   Google Scholar
• KIKUCHI M: Modulation of insulin secretion innon-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabet. Med. (1996) 13(9 Suppl. 6):S151–S155.
   Google Scholar
• SCHATZ H: Preclinical and clinical studies on safetyand tolerability of repaglinide. Exp. Clin. Endocrinol Diabetes (1999) 107\(Suppl. 4):S144–S148.
   Google Scholar
• GOMIS R: Repaglinide as monotherapy in Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes (1999) 107 (Suppl. 4):S133–S135.
   Google Scholar
• SCHWARTZ SL, STRANGE P: Repaglinide does not accumulate in patients with Type 2 diabetes. Diabetes (1998) 47 (Suppl. 1):A357.
   Google Scholar
• TRONIER B, MARBURY TC, DAMSBO P, WINDFELD K: A new oral hypoglycaemic agent, repaglinide, minimises risk of hypoglycaemia in well-controlled NIDDM patients. Diabetologia (1995) 38\(Suppl. 1):A752.
   Google Scholar
• •Initial evidence that prandial glucose regulation with repaglinide carries a lower risk of hypoglycaemia than conventional sulphonylurea treatment.
   Google Scholar
• HATORP V, BAYER T: Repaglinide bioavailability in the fed or fasting state. J. Gun. Pharmacol. (1997) 37:72.
   Google Scholar
• HATORP V, HUANG WC, STRANGE P: Pharmacokinetic profiles of repaglinide in elderly subjects with Type 2 diabetes. J. Clin. Endocrinol. Metab. (1999) 84 (4) :1475–1478.
   PubMed Web of Science ®Google Scholar
• HATORP V, HUANG WC, STRANGE P: Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Clin. Ther. (1999) 21(4):702–710.
   PubMed Web of Science ®Google Scholar
• HATORP V, HAUG-PIHALE G: A comparison of the pharmacokinetics of repaglinide in healthy subjects with that in subjects with chronic liver disease. Diabetologia (1998) 41 (Suppl. 1):A236.
   Google Scholar
• BAUER E, BESCHKE K, EBNER T et al.: Biotransformation of "C-repaglinide in human, cynomolgus monkey, dog, rabbit, rat and mouse. Diabetologia (1997) 40\(Suppl. 1):A326.
   Google Scholar
• SCHVVARTZ SL, GOLDBERG RB, STRANGE P: Repaglinide in Type 2 diabetes: a randomised, double-blind, placebo-controlled, dose-response study. Diabetes (1998) 47 (Suppl. 1):A98.
   Google Scholar
• WOLFFENBUTTEL BHR, NIJST L, SELS JPJE et al.: Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur. J. Clin. Pharmacol. (1993) 45 (2):113–116.
   PubMed Web of Science ®Google Scholar
• DAMSBO P, ANDERSEN PH, LUND S, PORKSEN N: Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal-related dosing. Diabetes (1997) 46\(Suppl. 1):A34.
   Google Scholar
• DAMSBO P, MARBURY TC, HATORP V, CLAUSON P, WILLER PG: Flexible providial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Res. Clin. Pract. (1999) 45 (0 :31–39.
   PubMed Web of Science ®Google Scholar
• ••Proof that prandial glucose regulation with repaglinide iseffective and safe even when the number of meals eaten each day is not fixed.
   Google Scholar
• WOLFFENBUTTEL BH, LANDGRAF R, FOR THE DUTCH AND GERMAN REPAGLINIDE STUDY GROUP: A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of Type 2 diabetes. Diabetes Care (1999) 22(3):463–467.
   PubMed Web of Science ®Google Scholar
• •First report of the long-term efficacy and safety of repaglinide monotherapy for the treatment of Type 2 diabetes.
   Google Scholar
• MARBURY T, HUANG WC, STRANGE P, LEBOVITZ H: Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. (1999) 43(3):155–166.
   PubMed Web of Science ®Google Scholar
• DEJGAARD A, MADSBAD S, KILHOVD B, LAGER I, MUSTAJOKI P: Repaglinide compared to glipizide in the treatment of Type 2 diabetic patients. Diabetologia (1998) 41 (Suppl. 1):A236.
   Google Scholar
• MOSES R: Repaglinide in combination therapy with metformin in Type 2 diabetes. Exp. Clin. Endocrinol Diabetes (1999) 107 (Suppl. 4):S136–139.
   Google Scholar
• ••Initial evidence that combination therapy with repaglinidecan produce synergistic improvements in glycaemic control.
   Google Scholar
• MOSES RG, SLOBODNIUK R, DONNELLY T et al.: Additional treatment with repaglinide provides significant improvement in glycemic control in NIDDM patients poorly controlled on metformin. Diabetes (1997) 46 (Suppl. 1):A93.
   Google Scholar
• LANDIN-OLSSON M, BROGARD J-MM, ERIKSSON J, RASMUSSEN M, CLAUSON P: The efficacy of repaglinide administered in combination with bedtime NPH-insulin in patients with Type 2 diabetes. Diabetes (1999) 48\(Suppl. 1):A117.
   Google Scholar
• ERIKSSON JG, BROGARD JM, LANDIN-OLSSON M, CLAUSON P, RASMUSSEN M: The safety of repaglinide administered in combination with bedtime NPH-insulin in patients with Type 2 diabetes. A randomized, semi-blinded, parallel-group, multi-centre trial. Diabetes (1999) 48\(Suppl. 1):A360.
   Google Scholar
• RASKIN P, GRAVELINE JF: Efficacy of troglitazone in combination with insulin in NIDDM. Diabetes (1997) 46:44A.
   Google Scholar
• MARBURY TC, HATORP V: Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers. Diabetes (1998) 47\(Suppl. 1):A357.
   Google Scholar
• DAMSBO P, PERENTESIS G, MULLER PG, HATORP V: Favourable tolerability profile of repaglinide in NIDDM after multiple ascending doses. J. Clin. Pharmacol. (1997) 37:71.
   Google Scholar